Ingredients

Fisetin vs Kaempferol: Structurally Similar Flavonoid Comparison

Written by ReCellence™ Editorial Team, Health Content SpecialistsReviewed by Medical Review Board, MD, PhDLast reviewed: March 7, 2026

Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.

What Each Is

Fisetin

Dietary Supplement

Fisetin (3,3′,4′,7-tetrahydroxyflavone) is found primarily in strawberries. Identified as the most potent dietary senolytic in 2018. Poor oral bioavailability.

Kaempferol

Dietary Supplement

Kaempferol (3,4′,5,7-tetrahydroxyflavone) is a common dietary flavonol found in kale, spinach, broccoli, tea, and beans. In the same 2018 senolytic screening, kaempferol showed substantially weaker senolytic activity than fisetin. Has its own preclinical research profile for anti-inflammatory, antioxidant, and potential cardioprotective effects.

Evidence Type Comparison

Understanding the difference in evidence quality between these options.

AspectFisetinKaempferol
FDA StatusNot FDA-approved for any conditionNot FDA-approved for any condition
Primary MechanismSenolytic (BCL-xL); NF-κB, Nrf2Anti-inflammatory, antioxidant, cardioprotective (weak senolytic)
Human Evidence StageEarly-stage (mostly safety)Very limited clinical data
Oral Bioavailability<10% (very poor)Poor, may be slightly better than fisetin
Dietary AbundanceLow (~0.2–1.4 mg/day)High (kale ~47 mg/100g, tea, broccoli)
Dosing ApproachIntermittent high-doseNot established

Mechanism Hypotheses (Conceptual)

Note: Mechanism hypotheses describe how compounds are thought to work based on laboratory research. This does not confirm clinical benefit or efficacy in humans.

Fisetin

Strong senolytic activity demonstrated in the 2018 flavonoid screen. BCL-xL inhibition drives senescent cell clearance. Also shows NF-κB inhibition, Nrf2 activation, and mTOR/AMPK modulation.

Kaempferol

A common dietary flavonol found in kale, spinach, tea, and broccoli. In the same 2018 senolytic screening, kaempferol showed substantially weaker senolytic activity than fisetin. However, kaempferol has its own research profile for anti-inflammatory, antioxidant, and potential cardioprotective effects.

Critical difference: The structural difference (kaempferol has OH at position 5 instead of 3′) appears to significantly affect senolytic potency, suggesting that the catechol group in fisetin's B-ring is important for BCL-xL binding.

Safety & Tolerability Patterns

Fisetin

Limited human safety data from clinical trials. Mild GI side effects. Very poor bioavailability (<10%).

Kaempferol

Consumed widely through vegetables and tea. Dietary safety is well-established. Supplemental safety data is limited. Bioavailability is also poor but may be slightly better than fisetin due to different metabolic pathways.

Key difference: Both are consumed as part of normal diets at low levels. Neither has extensive clinical trial safety data at supplemental doses.

Drug Interaction Considerations

Both fisetin and kaempferol may affect CYP3A4 and other drug-metabolizing enzymes. Neither is well characterized clinically.

Always discuss any supplements with your pharmacist, especially if you take prescription medications.

Decision Factors to Discuss Clinically

These factors should be discussed with your healthcare provider—not decided based on online information alone:

  • •Current medications and potential interactions
  • •Other health conditions (comorbidities)
  • •Symptom severity and impact on quality of life
  • •Your goals and preferences for treatment approach
  • •How you'll objectively track symptom changes

Questions to Bring to Your Appointment

Discussing supplements with your healthcare provider

1

Between these supplements, which has the most evidence for my goals?

Comparing options based on published clinical evidence

2

Could combining supplements increase side effect risk?

Understanding multi-ingredient formulas and interactions

3

How do I choose a quality supplement product?

Third-party testing, standardization, reputable brands

4

What's a reasonable trial period before deciding if a supplement works?

Timeline for evaluation

5

At what point should I consider prescription options instead?

Knowing when supplements aren't enough

Tip: Write down these questions before your appointment. Bring a list of all current medications and supplements you take, including dosages. Consider asking about objective symptom tracking to measure changes over time.

Quick Answers

Q1.

What is the difference between fisetin and kaempferol?

They are structurally similar flavonols differing by a single hydroxyl group. Fisetin has a catechol B-ring (3′,4′-OH); kaempferol has a mono-hydroxyl B-ring (4′-OH) plus a 5-OH. This small difference greatly affects senolytic potency.

Q2.

Is kaempferol a senolytic?

Kaempferol showed substantially weaker senolytic activity than fisetin in the 2018 screening. It is not considered a potent senolytic.

Q3.

Why is fisetin a better senolytic than kaempferol?

The catechol group (ortho-dihydroxyl) in fisetin's B-ring is hypothesized to be critical for BCL-xL binding. Kaempferol lacks this catechol arrangement, reducing senolytic potency.

Q4.

Which is more common in food?

Kaempferol is far more abundant, found in kale (~47 mg/100g), spinach, broccoli, tea, and beans. Fisetin is rare, mainly in strawberries.

Q5.

Should I eat more kale or strawberries?

For kaempferol, eat kale. For fisetin, eat strawberries. Both are healthy foods, but neither provides therapeutic senolytic doses — dietary intake is 100–1000× below research concentrations.

Q6.

Does kaempferol have health benefits?

Kaempferol has preclinical research for anti-inflammatory, antioxidant, and cardioprotective effects. Human clinical evidence is very limited.

Q7.

Can I take kaempferol supplements?

Kaempferol supplements exist but have very limited clinical data. Safety at supplemental doses is not well established. Fisetin has more research as a senolytic.

Q8.

Are they related to quercetin?

Yes. Fisetin, kaempferol, and quercetin are all flavonols sharing a common chemical scaffold but with different hydroxylation patterns that determine biological activity.

Q9.

Which has better bioavailability?

Both have poor oral bioavailability with extensive first-pass metabolism. Kaempferol's may be slightly better due to different metabolic pathways, but neither is well absorbed.

Q10.

Has kaempferol been tested in humans?

Kaempferol has very limited human clinical data, far less than fisetin. Most research is preclinical.

Q11.

Do they have the same side effects?

Both are generally well-tolerated in available data. Neither has extensive supplemental-dose safety data. Mild GI effects are most common.

Q12.

Why does one hydroxyl group matter so much?

Small structural changes in flavonoids significantly affect binding to target proteins like BCL-xL. The catechol group in fisetin's B-ring appears key for senolytic activity.

Q13.

Is there a clinical trial comparing them?

No. No clinical trial has directly compared fisetin and kaempferol for senolytic or any other health outcome.

Q14.

Which has more research overall?

Kaempferol has more preclinical studies due to its dietary abundance, but fisetin has more senolytic-focused research and more published human trials.

Q15.

Can I get enough of either from food?

No. Dietary intake of both is 100–1000× below concentrations used in preclinical research, making food-based therapeutic effects implausible.

Key Research Facts

1

Fisetin and kaempferol are structurally similar flavonols differing by a single hydroxyl group — fisetin has a catechol B-ring (3′,4′-OH) while kaempferol has a mono-hydroxyl B-ring (4′-OH).

Strong Evidence

Chemical structure analysis — Khan et al., 2013

2

In the 2018 senolytic screening, fisetin showed substantially stronger senolytic activity than kaempferol against human senescent cells.

Strong Evidence

Yousefzadeh et al., EBioMedicine — doi:10.1016/j.ebiom.2018.09.015

3

The catechol group (ortho-dihydroxyl) in fisetin's B-ring is hypothesized to be critical for BCL-xL binding and senolytic potency.

Moderate Evidence

Zhu et al., Aging — doi:10.18632/aging.101202

4

Kaempferol is far more abundant in the diet than fisetin, found in kale (~47 mg/100g), spinach, broccoli, and tea.

Strong Evidence

USDA Flavonoid Database — USDA food composition data

5

Neither fisetin nor kaempferol has demonstrated clinical efficacy for any health outcome in published human trials.

Strong Evidence

Literature review — PubMed search, 2026

6

No clinical trial has directly compared fisetin and kaempferol for senolytic or any other health outcome.

Strong Evidence

ClinicalTrials.gov — registry search

7

Kaempferol has its own preclinical research profile for anti-inflammatory and cardioprotective effects, distinct from its weak senolytic activity.

Moderate Evidence

Khan et al., Antioxidants & Redox Signaling — doi:10.1089/ars.2012.4901

8

Both fisetin and kaempferol have poor oral bioavailability, with extensive first-pass metabolism limiting systemic exposure.

Moderate Evidence

Grynkiewicz & Demchuk, Frontiers in Chemistry — doi:10.3389/fchem.2019.00159

9

Fisetin, kaempferol, and quercetin are all flavonols — sharing a common chemical scaffold but with different hydroxylation patterns that determine biological activity.

Strong Evidence

Khan et al., Antioxidants & Redox Signaling — doi:10.1089/ars.2012.4901

10

Dietary intake of both flavonols is 100–1000× below concentrations used in preclinical research, making food-based therapeutic effects implausible.

Strong Evidence

Dietary intake estimates — Khan et al., 2013

Continue Your Research

Explore related topics and take the next step in your cellular health journey.

Related Comparisons

Explore more head-to-head supplement comparisons backed by clinical evidence.

Citations & External Resources

Clinical Registry

ClinicalTrials.gov — Search: Fisetin

Review

PubMed — Fisetin research

Review

EBioMedicine — Yousefzadeh et al. 2018

Review

Aging — Zhu et al. 2017 (Senolytic Structure-Activity)

Review

Antioxidants & Redox Signaling — Khan et al. 2013 (Flavonoid Overview)

Related Reading

References (3)

Written by

ReCellence™ Editorial Team

Health Content Specialists

Medically reviewed by

Medical Review Board

MD, PhD

Last updated: March 8, 2026

Last medical review: March 8, 2026